ZDA
AERI

Zweig-DiMenna Associates’s Aerie Pharmaceuticals AERI Stock Holding History

Zweig-DiMenna Associates’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-25,000
Closed -$784K – 325
2015
Q1 		$784K Buy
+25,000
New +$725K 0.03% 146

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Zweig-DiMenna Associates's AERI Position: Q2 2015 in Review

Zweig-DiMenna Associates sold out of Aerie Pharmaceuticals (AERI) in Q2 2015, closing a stake of 25,000 shares — an estimated $784K sold.

Zweig-DiMenna Associates first reported a position in AERI in Q1 2015 and held it in 1 quarter. The position peaked at $784K in Q1 2015. 108 funds tracked by Wall St. Rank hold AERI as of Q2 2015.

  • Zweig-DiMenna Associates reported no remaining Aerie Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 25,000 Aerie Pharmaceuticals shares in Q2 2015, an estimated $784K.
  • Zweig-DiMenna Associates first reported a position in Aerie Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Zweig-DiMenna Associates's Aerie Pharmaceuticals position peaked at $784K in Q1 2015.
  • 108 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2015.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2015, filed 10 Aug 2015.